Drug intelligence / Profile preview

Kademin SCX

Development stage: Unknown
Lead developer: Provident Pharmaceuticals
Administration: Topical

Overview

Kademin SCX (marketed as KAdermin) is a topical medical device developed for wound management and skin protection. The product features the proprietary SCX technology, which consists of silicon dioxide functionalized with silver ions and chlorhexidine, creating a protective antimicrobial barrier against external pathogens. In addition to its antimicrobial properties, the formulation contains sodium hyaluronate (0.2%), aloe barbadensis, olive oil, and a blend of amino acids (L-lysine, L-proline, L-leucine, and glycine) that support tissue hydration and the physiological healing process. It is indicated for the treatment of minor wounds, burns, pressure sores, and other dermatological lesions.

Brand names: KAderminKademin SCX
Other names: KADERMIN

Beyond the preview

Go deeper on Kademin SCX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kademin SCX.

Explore the full profile